The combined therapy of lenvatinib with CDK2 inhibitors robustly induced tumor cell senescence and caused tumor growth suppression in vitro and in vivo, and dinaciclib or PF‐07104091 may be a candidate drug combined with lenvatinib for clinical therapy of ATC patients with high expression of CDK2. The gene discussed is CDK2; the disease is neoplasm.